Cytokinetics Inc
NASDAQ:CYTK

Watchlist Manager
Cytokinetics Inc Logo
Cytokinetics Inc
NASDAQ:CYTK
Watchlist
Price: 36.96 USD -0.73% Market Closed
Market Cap: 4.4B USD

Operating Margin
Cytokinetics Inc

-2 943.3%
Current
-5 434%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-2 943.3%
=
Operating Profit
-565.6m
/
Revenue
19.2m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Cytokinetics Inc
NASDAQ:CYTK
4.4B USD
-2 943%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
330.6B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
164B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
137.2B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.5B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
127.8B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.3B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Cytokinetics Inc
Glance View

Cytokinetics Inc., rooted firmly in the heart of California's biotechnology hub, has carved a niche in the complex arena of muscle biology. Founded in 1998, the company has focused its considerable expertise on the intricacies of muscle function, especially targeting conditions characterized by impaired muscle performance such as heart failure, ALS, and even SMA. Rather than pursuing the well-trodden paths of traditional pharmaceuticals, Cytokinetics delves into the uncharted realms of muscle contractility, leveraging its proprietary muscle biology expertise to develop small molecule therapeutics. Their pipeline is rich with candidates that promise to enhance muscle function, representing a blend of hope and scientific innovation for conditions that, until now, have seen few breakthroughs. As a business, Cytokinetics operates at the confluence of innovative science and strategic partnerships. Financially, the company nurtures its pipeline through the judicious blend of equity financing, collaboration revenues, and milestone payments. Strategic alliances with larger pharmaceutical companies, such as collaborations previously established with Amgen and Astellas, play a pivotal role; these partnerships not only provide capital but also benefit from shared resources and expanded market reach. With therapies still largely in development, the company's revenue streams are intertwined with the success of clinical trials and approvals, rendering each scientific step a potential catalyst for investor interest and market value growth.

CYTK Intrinsic Value
36 USD
Overvaluation 3%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-2 943.3%
=
Operating Profit
-565.6m
/
Revenue
19.2m
What is the Operating Margin of Cytokinetics Inc?

Based on Cytokinetics Inc's most recent financial statements, the company has Operating Margin of -2 943.3%.

Back to Top